You are here
Family Bank: StemCyte India
StemCyte India is the only cord blood bank in India having a ‘hybrid+ ‘ model that combines Private Banking, Public Banking, Advanced Therapeutics and Clinical trials. StemCyte India is a joint venture between StemCyte Inc., Apollo Hospital Enterprises Ltd., and Cadila Pharmaceuticals Ltd. StemCyte India began operations in 2010, and has delivered 43 cord blood therapies to date. In late 2016 StemCyte became the first cord blood bank in India to be accredited by FACT, and their CEO Mr Deepak Chhabra is now on the board of the international Cord Blood Association.
Labs and Locations
The laboratory of StemCyte India is located at Apollo Hospital Campus:
StemCyte India Therapeutics Pvt. Ltd.,
Plot No.1A, Apollo Hospital Campus,
Bhat GIDC Estate, Gandhinagar Ahmedabad Rd
Gandhinagar, Gujarat 382428, India
StemCyte India Therapeutics Pvt. Ltd. is a joint venture between three participants: StemCyte Inc., Apollo Hospital Enterprises Ltd. (the largest chain of private hospitals in Asia with 51 hospitals) and Cadila Pharmaceuticals Ltd. (a well-known pharma since three decades).
StemCyte Inc. was founded 1997 and is one of the earliest public/private "hybrid" cord blood banks. StemCyte Inc. is a global banking network with laboratories in USA, Taiwan, and India.
StemCyte India is operational since 2010, and its headquarter is strategically located in Ahmedabad with its processing and storage facility at Apollo Hospital campus, Gandhinagar and the sales force is spread all across India.
StemCyte the global company has (as of Aug, 2015) stored about 75,000 private cord blood units for clients and about 35,000 cord blood donations. StemCyte has released about 2000 transplants, with 43 from StemCyte India by the end of 2016.
In late 2016 StemCyte became the first cord blood bank in India to be accredited by FACT, and their CEO Mr Deepak Chhabra is now on the board of the international Cord Blood Association.
o StemCyte India provides a collection kit that is complete in every respect for cord blood collection & maternal blood collection as material used for it is having highest quality standards & truly imported. The collection bag is pre-filled with the anti-coagulant CPD and has a safety lock to avoid needle pricks and damages during collection. The kit includes Temperature stabilizing pack (Gel Pack -2); Cord Blood Collection kit (1).Maternal Sample Box (Temperature Stabilizing Pack) (1) and Cord Collection Vial.
o StemCyte India provides a cello insulated collection kit box which is fire resistant and tough hence no harm to the collected unit with excellent temperature maintenance
o We ensure that all supplies are well within the expiry date (at least 2 months) are kept in our validated, temperature-controlled cord blood collection shipping container in order to maintain the optimal temperature for transplantation of your baby's unique cells.
o StemCyte India arranges pickup of cord blood collection kits from all over India with the help of dedicated in-house team and their Logistics Partner (IATA Certified).
o StemCyte India ensures that umbilical cord blood stem cells should be delivered to their laboratory, processed, and stored within 48 hours of collection.
StemCyte India uses unique Plasma Depletion Technology patented by StemCyte Inc.:
o Only plasma is removed from the blood, preserving both red blood cells (RBC) and the buffy coat that holds stem cells
o Plasma depletion processing ensures up to 99.96 % stem cell recovery
o With plasma depletion, 70% of the total blood volume is stored
o StemCyte India's processing retains the VSELs in the blood (Very Small Embryonic-Like stem cells)
o StemCyte India saves from the Cord Blood: white blood cells (WBC), red blood cells (RBC), and stem cells (includes VSELs)
o StemCyte India's plasma depletion method results in a final cord blood stored volume of approx. 75 ml, which is HIGHEST IN THE INDUSTRY.
Licensing & Accreditation
o AABB (formerly American Association of Blood Banks) for Cord Blood
o DCGI (Drug Control General of India) licensed
o FACT (Foundation for the Accreditation of Cellular Therapy)
o ISO 9001: 2008 (International Standards Organisation)
o NABL (National Accreditation Board for Testing and Calibration Laboratories)
o WHO GMP for Blood Establishment
o StemCyte Inc. the international parent company has had cord blood units used in more than 2000 cord blood transplants across 315 transplant centers in 38 countries on 6 continents
o StemCyte Inc. has experience in treating 52 indications.
o StemCyte India has facilitated more than 40 transplants till date (Aug. 2015).
StemCyte is actively involved in clinical trials and research.
Current clinical trials are as follows:
o Spinal cord injury
o Cardiac repair
o Optic nerve degeneration
o Peripheral nerve repair
StemCyte India "Safeguard program" ensures:
o StemCyte India will provide up to 20 Lakh rupees for Transplant support (Varies according to plan chosen)
o If, StemCyte India fails to provide viable stem cells during retrieval, StemCyte will try to provide a matching sample from its international public inventory or would pay up to 20 Lakh rupees whichever is less, to the parents. (Varies according to plan chosen)
The price of our basic plan which includes cord blood and cord tissue collection, processing and storage for 21 years is as follows:
Enrollment fees : Rs. 5000 (81 $)
Processing charges : Rs. 20,000 (325 $)
Storage charges : Rs. 50,000 (814 $)
Total : Rs. 75,000 (1220 $)
StemCyte India offers several additional services:
1. One additional cord blood unit FREE
2. Transplant confirmatory tests FREE
3. HLA search FREE
4. Mesenchymal Stem Cells (MSC) storage FREE
5. Worldwide shipment of transplant FREE
6. Apollo transplant package included